lncRNA cytoskeleton regulator reduces non‑small cell lung cancer radiosensitivity by downregulating miRNA‑206 and activating prothymosin α

Jiang,Guoxiang; Yu,Honge; Li,Zhengliang; Zhang,Fang

doi:10.3892/ijo.2021.5268

lncRNA cytoskeleton regulator reduces non‑small cell lung cancer radiosensitivity by downregulating miRNA‑206 and activating prothymosin α

Authors:
- Guoxiang Jiang
- Honge Yu
- Zhengliang Li
- Fang Zhang
View Affiliations

Affiliations: Department of Oncology Radiotherapy, Yantaishan Hospital, Yantai, Shandong 264000, P.R. China, Department of Oncology, People's Hospital of Haiyang, Haiyang, Shandong 265100, P.R. China, Department of Oncology Radiotherapy, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong 264100, P.R. China
Published online on: September 23, 2021 https://doi.org/10.3892/ijo.2021.5268
Article Number: 88
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to explore the role of the long noncoding RNA cytoskeleton regulator (CYTOR) in non‑small cell lung cancer (NSCLC) radiosensitivity by manipulating the microRNA (miR)‑206/prothymosin α (PTMA) axis. First, 58 pairs of NSCLC and paracancerous tissues, normal human lung epithelial cells and NSCLC cells were collected to analyze CYTOR expression and the relationship between CYTOR and NSCLC prognosis. Subsequently, CYTOR expression in radioresistant cells was assessed. Radioresistant cells with low CYTOR expression and parental cells with high CYTOR expression were established. Functional assays were then performed to assess changes in cell radiosensitivity after irradiation treatment. Subsequently, the downstream mechanism of CYTOR was explored. The binding interactions between CYTOR and miR‑206 and between miR‑206 and PTMA were predicted and certified. Xenograft transplantation was applied to confirm the role of CYTOR in the radiosensitivity of NSCLC. CYTOR was overexpressed in NSCLC and was associated with poor prognosis. CYTOR was further upregulated in NSCLC cells with radioresistance. CYTOR knockdown enhanced the radiosensitivity of NSCLC cells, while overexpression of CYTOR led to the opposite result. Mechanistically, CYTOR specifically bound to miR‑206 and silencing CYTOR promoted miR‑206 to enhance the radiosensitivity of NSCLC cells. PTMA is a target of miR‑206 and silencing CYTOR inhibited PTMA expression via miR‑206, thus promoting radiosensitivity of NSCLC cells. CYTOR knockdown also enhanced NSCLC cell radiosensitivity in vivo. CYTOR was highly expressed in NSCLC, while silencing CYTOR potentiated NSCLC cell radiosensitivity by upregulating miR‑206 and suppressing PTMA. The present study preliminarily revealed the role of CYTOR in radiotherapy sensitivity of NSCLC and provided a novel potential target for the clinical treatment of NSCLC.

View Figures

View References

1	Chen Z, Fillmore CM, Hammerman PS, Kim CF and Wong KK: Non-small-cell lung cancers: A heterogeneous set of diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar
2	Tandberg DJ, Tong BC, Ackerson BG and Kelsey CR: Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. Cancer. 124:667–678. 2018. View Article : Google Scholar
3	Rafei H, El-Bahesh E, Finianos A, Nassereddine S and Tabbara I: Immune-based therapies for non-small cell lung cancer. Anticancer Res. 37:377–387. 2017. View Article : Google Scholar
4	Elias R, Morales J and Presley C: Checkpoint inhibitors for non-small cell lung cancer among older adults. Curr Oncol Rep. 19:622017. View Article : Google Scholar
5	Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L and Rosell R: Non-small-cell lung cancer. Nat Rev Dis Primers. May 21–2015.Epub ahead of print. View Article : Google Scholar
6	Skřičková J, Kadlec B, Venclíček O and Merta Z: Lung cancer. Cas Lek Cesk. 157:226–236. 2018.
7	Liang J, Lu T, Chen Z, Zhan C and Wang Q: Mechanisms of resistance to pemetrexed in non-small cell lung cancer. Transl Lung Cancer Res. 8:1107–1118. 2019. View Article : Google Scholar
8	Tabchi S, Kassouf E, Rassy EE, Kourie HR, Martin J, Campeau MP, Tehfe M and Blais N: Management of stage III non-small cell lung cancer. Semin Oncol. 44:163–177. 2017. View Article : Google Scholar
9	Pennell NA, Arcila ME, Gandara DR and West H: Biomarker testing for patients with advanced non-small cell lung cancer: Real-world issues and tough choices. Am Soc Clin Oncol Educ Book. 39:531–542. 2019. View Article : Google Scholar
10	Huang Q: Predictive relevance of ncRNAs in non-small-cell lung cancer patients with radiotherapy: A review of the published data. Biomarkers Med. 12:1149–1159. 2018. View Article : Google Scholar
11	Bhan A, Soleimani M and Mandal SS: Long noncoding RNA and cancer: A New Paradigm. Cancer Res. 77:3965–3981. 2017. View Article : Google Scholar
12	Yu H and Li SB: Role of LINC00152 in non-small cell lung cancer. J Zhejiang Univ Sci B. 21:179–191. 2020. View Article : Google Scholar
13	Yue B, Liu C, Sun H, Liu M, Song C, Cui R, Qiu S and Zhong M: A positive feed-forward loop between LncRNA-CYTOR and Wnt/β-catenin signaling promotes metastasis of colon cancer. Mol Ther. 26:1287–1298. 2018. View Article : Google Scholar :
14	Moradi MT, Hatami R and Rahimi Z: Circulating CYTOR as a potential biomarker in breast cancer. Int J Mol Cell Med. 9:83–90. 2020.
15	Liu Y, Li M, Yu H and Piao H: lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR 125a 5p. Int J Mol Med. 45:497–509. 2020.
16	Chen S, Yang M, Wang C, Ouyang Y, Chen X, Bai J, Hu Y, Song M, Zhang S and Zhang Q: Forkhead box D1 promotes EMT and chemoresistance by upregulating lncRNA CYTOR in oral squamous cell carcinoma. Cancer Lett. 503:43–53. 2021. View Article : Google Scholar
17	Zhu H, Shan Y, Ge K, Lu J, Kong W and Jia C: LncRNA CYTOR promotes pancreatic cancer cell proliferation and migration by sponging miR-205-5p. Pancreatology. 20:1139–1148. 2020. View Article : Google Scholar
18	Li M, Wang Q, Xue F and Wu Y: lncRNA-CYTOR works as an Oncogene through the CYTOR/miR-3679-5p/MACC1 axis in colorectal cancer. DNA Cell Biol. 38:572–582. 2019. View Article : Google Scholar
19	Hu B, Yang XB, Yang X and Sang XT: LncRNA CYTOR affects the proliferation, cell cycle and apoptosis of hepatocellular carcinoma cells by regulating the miR-125b-5p/KIAA1522 axis. Aging (Albany NY). 13:2626–2639. 2020. View Article : Google Scholar
20	Petrek H and Yu AM: MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential. Pharmacol Res Perspect. 7:e005282019. View Article : Google Scholar
21	Shengnan J, Dafei X, Hua J, Sunfu F, Xiaowei W and Liang X: Long non-coding RNA HOTAIR as a competitive endogenous RNA to sponge miR-206 to promote colorectal cancer progression by activating CCL2. J Cancer. 11:4431–4441. 2020. View Article : Google Scholar
22	Cao HL, Liu ZJ, Huang PL, Yue YL and Xi JN: lncRNA-RMRP promotes proliferation, migration and invasion of bladder cancer via miR-206. Eur Rev Med Pharmacol Sci. 23:1012–1021. 2019.
23	Liao M and Peng L: MiR-206 may suppress non-small lung cancer metastasis by targeting CORO1C. Cell Mol Biol Lett. 25:222020. View Article : Google Scholar
24	Samaeekia R, Adorno-Cruz V, Bockhorn J, Chang YF, Huang S, Prat A, Ha N, Kibria G, Huo D, Zheng H, et al: miR-206 inhibits stemness and metastasis of breast cancer by targeting MKL1/IL11 pathway. Clin Cancer Res. 23:1091–1103. 2017. View Article : Google Scholar
25	Jiao D, Chen J, Li Y, Tang X, Wang J, Xu W, Song J, Li Y, Tao H and Chen Q: miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT. J Cell Mol Med. 22:3526–3536. 2018. View Article : Google Scholar
26	Weidle UH, Birzele F and Nopora A: MicroRNAs as potential targets for therapeutic intervention with metastasis of non-small cell lung cancer. Cancer Genomics Proteomics. 16:99–119. 2019. View Article : Google Scholar
27	Zhu Y, Qi X, Yu C, Yu S, Zhang C, Zhang Y, Liu X, Xu Y, Yang C, Jiang W, et al: Identification of prothymosin alpha (PTMA) as a biomarker for esophageal squamous cell carcinoma (ESCC) by label-free quantitative proteomics and Quantitative Dot Blot (QDB). Clin Proteomics. 16:122019. View Article : Google Scholar
28	Sandow JJ, Rainczuk A, Infusini G, Makanji M, Bilandzic M, Wilson AL, Fairweather N, Stanton PG, Garama D, Gough D, et al: Discovery and validation of novel protein biomarkers in ovarian cancer patient urine. Proteomics Clin Appl. 12:e17001352018. View Article : Google Scholar : PubMed/NCBI
29	Li JH, Liu S, Zhou H, Qu LH and Yang JH: starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 42:D92–D97. 2014. View Article : Google Scholar
30	Yan F, Zhao W, Xu X, Li C, Li X, Liu S, Shi L and Wu Y: LncRNA DHRS4-AS1 inhibits the stemness of NSCLC cells by sponging miR-224-3p and upregulating TP53 and TET1. Front Cell Dev Biol 2020. 8:5852512020. View Article : Google Scholar
31	Li Z, Qu Z, Wang Y, Qin M and Zhang H: miR-101-3p sensitizes non-small cell lung cancer cells to irradiation. Open Med (Wars). 15:413–423. 2020. View Article : Google Scholar
32	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
33	Zamani M, Etebari M and Moradi SH: The increment of genoprotective effect of melatonin due to 'Autooptic' effect versus the genotoxicity of mitoxantrone. J Biomed Phys Eng. 10:771–782. 2020.
34	Paraskevopoulou MD, Vlachos IS, Karagkouni D, Georgakilas G, Kanellos I, Vergoulis T, Zagganas K, Tsanakas P, Floros E, Dalamagas T, et al: DIANA-LncBase v2: Indexing microRNA targets on non-coding transcripts. Nucleic Acids Res. 44:D231–D238. 2016. View Article : Google Scholar
35	Jeggari A, Marks DS and Larsson E: miRcode: A map of putative microRNA target sites in the long non-coding transcriptome. Bioinformatics. 28:2062–2063. 2012. View Article : Google Scholar
36	Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. eLife. 4:20152015. View Article : Google Scholar
37	Huang HY, Lin YC, Li J, Huang KY, Shrestha S, Hong HC, Tang Y, Chen YG, Jin CN, Yu Y, et al: miRTarBase 2020: Updates to the experimentally validated microRNA-target interaction database. Nucleic Acids Res. 48:D148–D154. 2020.
38	Wang L, Tong X, Zhou Z, Wang S, Lei Z, Zhang T, Liu Z, Zeng Y, Li C, Zhao J, et al: Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-β-induced epithelial-mesenchymal transition and metastasis by controlling TIF1γ in non-small cell lung cancer. Mol Cancer. 17:1402018. View Article : Google Scholar
39	Jones-Bolin S: Guidelines for the care and use of laboratory animals in biomedical research. Curr Protoc Pharmacol 2012 Appendix. 4:4B2012.
40	Wang T, Dong XM, Zhang FL and Zhang JR: miR-206 enhances nasopharyngeal carcinoma radiosensitivity by targeting IGF1. Kaohsiung J Med Sci. 33:427–432. 2017. View Article : Google Scholar
41	Ojima E, Inoue Y, Miki C, Mori M and Kusunoki M: Effectiveness of gene expression profiling for response prediction of rectal cancer to preoperative radiotherapy. J Gastroenterol. 42:730–736. 2007. View Article : Google Scholar : PubMed/NCBI
42	Chiu YH, Hsu SH, Hsu HW, Huang KC, Liu W, Wu CY, Huang WP, Chen JY, Chen BH and Chiu CC: Human non small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy. Int J Oncol. 53:1967–1979. 2018.
43	Osielska MA and Jagodziński PP: Long non-coding RNA as potential biomarkers in non-small-cell lung cancer: What do we know so far? Biomed Pharmacother. 101:322–333. 2018. View Article : Google Scholar
44	Liang J, Wei X, Liu Z, Cao D, Tang Y, Zou Z, Zhou C and Lu Y: Long noncoding RNA CYTOR in cancer: A TCGA data review. Clin Chim Acta. 483:227–233. 2018. View Article : Google Scholar : PubMed/NCBI
45	Yu Y, Yang J, Li Q, Xu B, Lian Y and Miao L: LINC00152: A pivotal oncogenic long non-coding RNA in human cancers. Cell Prolif. 50:20172017.
46	Quan FY, Jiang J, Zhai YF, Li B, Wu XH and Nie W: The prognostic effect of LINC00152 for cancer: A meta-analysis. Oncotarget. 8:75427–75433. 2017. View Article : Google Scholar
47	Mao Y, Tie Y, Du J and He J: LINC00152-promotes the proliferation of gastric cancer cells by regulating B-cell lymphoma-2. J Cell Biochem. 120:3747–3756. 2019. View Article : Google Scholar
48	Li N, Feng XB, Tan Q, Luo P, Jing W, Zhu M, Liang C, Tu J and Ning Y: Identification of circulating long noncoding RNA Linc00152 as a novel biomarker for diagnosis and monitoring of non-small-cell lung cancer. Dis Markers. 2017:74396982017. View Article : Google Scholar
49	Feng S, Zhang J, Su W, Bai S, Xiao L, Chen X, Lin J, Reddy RM, Chang AC, Beer DG and Chen G: Overexpression of LINC00152 correlates with poor patient survival and knockdown impairs cell proliferation in lung cancer. Sci Rep. 7:29822017. View Article : Google Scholar
50	Zhang J and Li W: Long noncoding RNA CYTOR sponges miR-195 to modulate proliferation, migration, invasion and radiosensitivity in nonsmall cell lung cancer cells. Biosci Rep. 38:20182018. View Article : Google Scholar
51	Zou H and Li H: Knockdown of long non-coding RNA LINC00152 increases cisplatin sensitivity in ovarian cancer cells. Exp Ther Med. 18:4510–4516. 2019.
52	Sun Z, Guo X, Zang M, Wang P, Xue S and Chen G: Long non-coding RNA LINC00152 promotes cell growth and invasion of papillary thyroid carcinoma by regulating the miR-497/BDNF axis. J Cell Physiol. 234:1336–1345. 2019. View Article : Google Scholar
53	Ma P, Wang H, Sun J, Liu H, Zheng C, Zhou X and Lu Z: LINC00152 promotes cell cycle progression in hepatocellular carcinoma via miR-193a/b-3p/CCND1 axis. Cell Cycle. 17:974–984. 2018. View Article : Google Scholar
54	Chang L, Guo R, Yuan Z, Shi H and Zhang D: LncRNA HOTAIR regulates CCND1 and CCND2 expression by sponging miR-206 in ovarian cancer. Cell Physiol Biochem. 49:1289–1303. 2018. View Article : Google Scholar
55	Ren D, Zheng H, Fei S and Zhao JL: MALAT1 induces osteosarcoma progression by targeting miR-206/CDK9 axis. J Cell Physiol. 234:950–957. 2018. View Article : Google Scholar
56	Wang Y, Xu H, Si L, Li Q, Zhu X, Yu T and Gang X: MiR-206 inhibits proliferation and migration of prostate cancer cells by targeting CXCL11. Prostate. 78:479–490. 2018. View Article : Google Scholar
57	Wang P, Gu J, Wang K, Shang J and Wang W: miR-206 inhibits thyroid cancer proliferation and invasion by targeting RAP1B. J Cell Biochem. 120:18927–18936. 2019. View Article : Google Scholar : PubMed/NCBI
58	Dai C, Xie Y, Zhuang X and Yuan Z: MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway. Biomed Pharmacother. 104:763–770. 2018. View Article : Google Scholar
59	Liu F, Yin R, Chen X, Chen W, Qian Y, Zhao Y, Jiang Y, Ma D, Hu T, Yu T, et al: Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma. Biomed Pharmacother. 114:1086052019. View Article : Google Scholar
60	Jia KG, Feng G, Tong YS, Tao GZ and Xu L: miR-206 regulates non-small-cell lung cancer cell aerobic glycolysis by targeting hexokinase 2. J Biochem. 167:365–370. 2020. View Article : Google Scholar
61	Yang L, Sun H, Liu X, Chen J, Tian Z, Xu J, Xiang B and Qin B: Circular RNA hsa_circ_0004277 contributes to malignant phenotype of colorectal cancer by sponging miR-512-5p to upregulate the expression of PTMA. J Cell Physiol. Jan 21–2020.Epub ahead of print. View Article : Google Scholar
62	Yang C, Zhang J, Ding M, Xu K, Li L, Mao L and Zheng J: Ki67 targeted strategies for cancer therapy. Clin Transl Oncol. 20:570–575. 2018. View Article : Google Scholar
63	Wierzbicka-Tutka I, Sokołowski G, Bałdys-Waligórska A, Adamek D, Radwańska E and Gołkowski F: Prothymosin-alpha and Ki-67 expression in pituitary adenomas. Postepy Hig Med Dosw. 70:1117–1123. 2016. View Article : Google Scholar
64	Wang Y, Li M, Dong C, Ma Y, Xiao L, Zuo S, Gong Y, Ren T and Sun B: Linc00152 knockdown inactivates the Akt/mTOR and Notch1 pathways to exert its anti-hemangioma effect. Life Sci. 223:22–28. 2019. View Article : Google Scholar
65	Du L, Huang GH, Mou KJ, Xiang Y, Tang JH, Xu W, Xia SL, Zhao JN and Lv SQ: MiR-206 is down-regulated and suppresses cell proliferation by targeting FOXP1 in brain gliomas. Int J Clin Exp Pathol. 11:3405–3415. 2018.